Collagen

ModerateRecurrent calcium oxalate nephrolithiasisGrade C

Hydroxyproline is a significant endogenous oxalate precursor via the glyoxylate pathway.

ModerateHistamine intolerance / mast cell activation syndrome (MCAS)Grade C

Bone broth and incompletely hydrolyzed collagen contain histamine and histidine-derived biogenic amines. Hydroxyproline may compete with histamine for DAO enzyme.

ModeratePregnancy — high-dose supplementation (>10 g/day)Grade D

No human teratogenicity data. High glycine load: effects on placental amino acid transport and fetal collagen dynamics unknown.

ModerateLactation / breastfeedingGrade D

Precautionary principle applies.

ModerateSevere hepatic impairment (Child-Pugh B/C)Grade D

Impaired amino acid deamination and urea cycle function. High glycine load (~2.7 g per 10 g collagen) may worsen hyperammonemia and hepatic encephalopathy.

ModerateSystemic sclerosis (scleroderma) / progressive fibrotic conditionsGrade D

Scleroderma is driven by pathological TGF-β1 signaling → excessive COL1A1/COL3A1 deposition. Exogenous Pro-Hyp stimulates TGF-β1 in fibroblasts — the same pathway that drives disease progression.

ModeratePre-operative period (≤2 weeks before major elective surgery)Grade D

High glycine loading may potentiate glycine receptor-mediated CNS inhibition and theoretical anesthetic depth modulation. Standard pre-operative supplement cessation protocol applies.

ModerateActive gout or hyperuricemia (uric acid >9 mg/dL)Grade D

Glycine is a purine ring precursor (C4, C5, N7). High glycine loads from collagen (>15 g/day) could marginally increase uric acid via purine synthesis flux.

ModerateActive inflammatory bowel disease flare (Crohn's, UC)Grade D

Active IBD downregulates PEPT-1 expression and reduces absorptive surface area. Peptide fragments may trigger immune activation through disrupted mucosal barrier.

ModeratePediatric use (<18 years) — supplement dosesGrade D

No safety/efficacy data in pediatric populations. Developing collagen matrix during growth may be susceptible to exogenous peptide signaling.

ModerateGlucocorticoids (prednisone, dexamethasone, cortisol)Grade C

Glucocorticoids suppress COL1A1/COL1A2 transcription via GR-mediated repression and increase MMP expression.

ModerateCopper chelators (penicillamine, trientine)Grade C

Copper is required cofactor for LOX and LOXL1-4; chelation reduces cross-linking enzyme activity and impairs collagen/elastin maturation.

ModerateGlucocorticoids (prednisone, dexamethasone, prednisolone)Grade C

Glucocorticoids suppress fibroblast collagen gene transcription (COL1A1, COL3A1) and upregulate MMPs; collagen supplementation partially counteracts this catabolic signal via Pro-Hyp → TGF-β1 axis.

ModerateCopper chelators (D-penicillamine, trientine)Grade C

Lysyl oxidase (LOX) requires copper as essential cofactor for collagen and elastin crosslinking. D-penicillamine (used in Wilson's disease, RA) chelates copper → impairs LOX activity → reduces collagen fibril crosslink formation → collagen supplementation provides substrate but…

ModerateFluoroquinolones (ciprofloxacin, levofloxacin, moxifloxacin)Grade D

Fluoroquinolones chelate divalent cations (Mg²⁺, Fe²⁺, Zn²⁺) and inhibit tendon fibroblast collagen synthesis; concurrent use may not offset fluoroquinolone tendinopathy risk

ModerateMethotrexateGrade D

Methotrexate inhibits DHFR, reducing folate availability for one-carbon metabolism; indirectly impairs collagen cross-linking by limiting methylation reactions and possibly homocysteine-mediated LOX inhibition

ModerateWarfarin / Vitamin K antagonistsGrade D

Collagen peptides have no known effect on CYP2C9 (warfarin metabolism) or VKORC1. No direct pharmacokinetic interaction expected.

MinorAscorbic acid (Vitamin C)Grade B

Vitamin C is obligate cofactor for prolyl-4-hydroxylase (P4HA) and lysyl hydroxylase (PLOD) enzymes required for collagen triple-helix stability; without ascorbate, collagen synthesized from supplemental peptides cannot be properly hydroxylated and cross-linked

MinorNSAIDs (ibuprofen, naproxen, celecoxib, diclofenac)Grade C

NSAIDs inhibit COX-1/COX-2, reducing prostaglandin-mediated inflammation; may blunt the transient post-exercise collagen synthetic response that collagen supplementation aims to enhance.

MinorEstrogens (oral contraceptives, HRT: estradiol, ethinylestradiol)Grade C

Estrogen upregulates COL1A1/COL1A2 expression and inhibits MMP-1/MMP-3 collagenases; synergistic with exogenous collagen peptides for dermal and bone matrix maintenance

MinorNSAIDs (ibuprofen, naproxen, diclofenac)Grade C

COX inhibition reduces PGE2-mediated fibroblast activation and post-exercise collagen synthesis signal; may blunt collagen remodelling response to exercise + supplementation

MinorEstrogens (HRT, oral contraceptives)Grade C

ERα/ERβ signalling upregulates COL1A1/COL3A1 transcription and inhibits MMP-1/3; exogenous estrogens amplify collagen synthesis — additive with supplementation

MinorHigh-dose zinc supplementation (>40 mg/day)Grade C

High zinc inhibits copper absorption (metallothionein competition); secondary copper deficiency impairs LOX-dependent collagen cross-linking.

MinorZinc supplements (>40 mg/day elemental zinc)Grade C

Standard dietary zinc intake does not cause this.

MinorNon-steroidal anti-inflammatory drugs (NSAIDs: ibuprofen, naproxen, aspirin high-dose, celecoxib)Grade D

NSAIDs inhibit COX-1/COX-2, reducing prostaglandin E2 (PGE2). COX inhibition in the post-exercise period may blunt the anabolic collagen synthesis window during which supplementation substrate is utilized.

MinorMethotrexate (low-dose 7.5–25 mg/week, rheumatologic)Grade D

Methotrexate inhibits dihydrofolate reductase (DHFR), depleting cellular tetrahydrofolate pool. Folate is required for serine-glycine interconversion via serine hydroxymethyltransferase (SHMT).

MinorProton pump inhibitors (omeprazole, pantoprazole, lansoprazole, esomeprazole)Grade D

Gastric acid (pH 1–2) and pepsin initiate denaturation and early proteolysis of collagen protein. PPIs raise intragastric pH to 4–6, reducing peptic pre-digestion efficiency.

MinorIsotretinoin (13-cis-retinoic acid)Grade D

topical and systemic retinoids at appropriate concentrations upregulate COL1A1 and COL3A1 in dermal fibroblasts but also increase MMP-1. The net interaction with concurrent oral collagen supplementation on skin collagen content is not characterized.

MinorWarfarin (and other vitamin K antagonists: acenocoumarol, phenprocoumon)Grade D

No direct pharmacokinetic interaction between purified collagen hydrolysate and warfarin metabolism. Collagen is not a CYP2C9 substrate or inhibitor.

MinorCalcineurin inhibitors (cyclosporine, tacrolimus)Grade D

Calcineurin inhibitors cause gingival overgrowth and organ fibrosis partly via TGF-β1 upregulation, which transcriptionally drives COL1A1/COL3A1 overexpression in fibroblasts. Providing additional collagen substrate via supplementation in patients on cyclosporine/tacrolimus is…

MinorStatins (HMG-CoA reductase inhibitors: atorvastatin, rosuvastatin, simvastatin, pravastatin)Grade D

Statins deplete mevalonate pathway intermediates (geranylgeranyl-PP, farnesyl-PP) required for Rho GTPase prenylation. Rho/ROCK signaling regulates actin cytoskeletal tension and downstream TGF-β1/SMAD collagen synthesis signaling in fibroblasts.

MinorGlucocorticoids (topical: triamcinolone, fluocinolone)Grade D

Topical glucocorticoids cause local collagen degradation via MMP upregulation and collagen synthesis inhibition; oral collagen hydrolysate may partially restore dermal collagen density via systemic Pro-Hyp delivery

MinorTetracyclines (doxycycline, minocycline)Grade D

mechanistically synergistic with collagen supplementation by reducing collagen degradation while supplementation increases synthesis

MinorProton pump inhibitors (omeprazole, pantoprazole, lansoprazole)Grade D

PPIs suppress gastric acid; elevated gastric pH may reduce pepsin-mediated pre-digestion of collagen protein, shifting hydrolysis burden to pancreatic proteases.

MinorWarfarin and other vitamin K antagonistsGrade D

Collagen hydrolysate contains glycine (major amino acid); glycine supplementation has been shown in isolated case reports to mildly affect INR via unknown mechanism, possibly through effects on CYP2C9 enzyme expression.

MinorStatins (atorvastatin, rosuvastatin, simvastatin)Grade D

Statins inhibit HMG-CoA reductase; mevalonate pathway products (geranylgeranyl pyrophosphate) regulate Rho GTPase activity important for fibroblast collagen synthesis.

MinorProton pump inhibitors (omeprazole, lansoprazole, pantoprazole)Grade D

Elevated gastric pH reduces pepsin activity; pepsin is primary initiator of collagen hydrolysis in stomach.

MinorIsotretinoin (13-cis retinoic acid)Grade D

Isotretinoin downregulates COL1A1/COL3A1 via RAR-mediated transcriptional repression in fibroblasts; paradoxical — reduces sebum but may impair dermal collagen quality

MinorWarfarinGrade D

No direct PK interaction (no CYP450); glycine (collagen breakdown product) GABA-A activity theoretical